NCT02868697 - Management of Tunneled Catheter Thrombosis in Hemodialysis Patients: Prospective Study From Qatar | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions

Hemodialysis, Tunneled Catheter, Qatar

Interventions

DRUG

TauroLock U 25000

taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000

DRUG

(TauroLock Hep500)

1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4'-methylenebis\[tetrahydro-1,1,1',1'-tetraoxide\], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH

Trial Locations (1)

30550

Fahd Bin Jassem Dialysis Centre, Doha